Study of new onset cutaneous manifestations in Rheumatic Diseases
Abstract
Background: Skin manifestations are an important clue to underlying rheumatological conditions and at times the first manifestation of the disease. Their identification helps in diagnosis, classification and follow up of these diseases. Hence we conducted this study to assess the new onset cutaneous lesions in patients with rheumatic diseases and correlate skin lesions with disease activity and study the response to therapy over a period of 3 months.
Materials and Methods: This prospective observational study was done in KEM Hospital, Mumbai over 18 months recruiting 78 patients, presenting to Rheumatology OPD / wards with new onset skin manifestations. Disease activity was calculated as per standard indices for each rheumatological disease. Skin lesions appearing due to adverse effects of drugs or unrelated to the disease were excluded from the study. The outcome of the skin lesions was assessed at 3 months follow up.
Results: Mean age of patients was 38 years with 91% being females. SLE was the most common diagnosis. The most common skin lesions were malar rash among SLE patients; rheumatoid nodules in patients of RA; Sclerodactyly in the Scleroderma patients and Heliotrope rash amongst the dermatomyositis patients. The mean SLEDAI score in the group with LE non -specific lesions was significantly higher compared to the group with LE-specific lesions (P<0.0001). At 3 months there was statistically significant reduction in SLEDAI score after treatment in SLE patients. In patients of RA, 74% patients showed reduction in DAS 28 ESR score with treatment at 3 months. Systemic sclerosis patients failed to show significant improvement in Modified Rodnan’s Skin Score after 3 months of treatment.
Conclusions: Among all rheumatological conditions SLE presents most often with skin involvement. Patients with LE specific lesions have lower disease activity (SLEDAI score) as compared to LE nonspecific lesions. At 3 months follow up the response to treatment is good in SLE patients with reduction in SLEDAI scores and also in RA patients with reduction in DAS 28 ESR scores.
Downloads
References
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep; 40(9):1725. DOI: https://doi.org/10.1002/art.1780400928
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7.
Wananukul S, Watana D, Pongprast P. Cutaneous manifestations of childhood systemic lupus erythematosus. Pediatr Dermatol. 1998;15:342-6.
O'Quinn SE, Cole J, Many H. Problems of disability and rehabilitation in patients with chronic skin diseases. Arch Dermatol. 1972 Jan;105(1):35-41.
Kole AK, Ghosh A. Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center. Indian J Dermatol. 2009;54(2):132-6. doi: https://dx.doi.org/10.4103%2F0019-5154.53189.
Lee HH1, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007 Mar;156(3):486-91. DOI: https://doi.org/10.1111/j.1365-2133.2007.07682.x.
Aflak Rasheed, Shazia Rasul, Abdul Hameed. Prevalence of usual and unusual skin manifestations of systemic lupus erythematosus in a tertiary care hospital. Journal of Pakistan Association of Dermatologists. 2016;26 (2):118-122
Laman SD, Provost TT. Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am. 1994 Feb;20(1):195-212.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8. doi: http://dx.doi.org/10.1136/ard.2010.138461.
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91.
Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997 May;40(5):809-13. DOI: https://doi.org/10.1002/art.1780400506.
Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):44-8.
Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993 Nov;20(11):1892-6.
Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis. 1982 Apr;8(1):207-18.
Yamamoto T. Cutaneous manifestations associated with rheumatoid arthritis. Rheumatol Int. 2009 Jul;29(9):979-88. doi: https://doi.org/10.1007/s00296-009-0881-z. Epub 2009 Feb 26.
Masi AT, Kaslow RA. Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum. 1978 May;21(4):480-4.
Prakash B, CA Jayashankar, Shivalingappa VM, Bhakthavatsalam SA, Chandrashekar K. Cutaneous Manifestations of Rheumatoid Arthritis. IJRCI. 2015;3(1):OA2. DOI: https://doi.org/10.15305/ijrci/v3i1/107.
Das NK, Dutta RN, Sengupta SR. Skin lesions in lupus erythematosus: a marker of systemic involvement. Indian J Dermatol. 2011 Sep-Oct;56(5):537-40. doi: https://dx.doi.org/10.4103%2F0019-5154.87150.
Malaviya AN, Singh RR, Kumar A, et al. Systemic lupus erythematosus in northern India: a review of 329 cases. J Assoc Physicians India. 1988 Aug;36(8):476-80, 484.
Feng PH, Boey ML. Systemic lupus erythematosus in Chinese: the Singapore experience. Rheumatol Int. 1982;2(4):151-4.
Vaidya S, Samant RS. SLE-review of two hundred and twenty patients. J India Rheumatol Assoc 1997;5:14-8.
Kapadia N, Haroon TS. Cutaneous manifestations of systemic lupus erythematosus: study from Lahore, Pakistan. Int J Dermatol. 1996 Jun;35(6):408-9.
Zecević RD, Vojvodić D, Ristić B, et al. Skin lesions--an indicator of disease activity in systemic lupus erythematosus? Lupus. 2001;10(5):364-7. DOI: https://doi.org/10.1191%2F096120301675962535
Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations. DOI: https://doi.org/10.1016/j.jaad.2004.07.023.
Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994 Jan;21(1):33-6.
Cojocaru M, Cohocaru IM, Chico B. New insight into the rheumatoid vasculitis. Rom J Intern Med. 2015 Apr-Jun;53(2):128-32. DOI: https://doi.org/10.1515/rjim-2015-0017.
Sharma A, Albert D (2015) Dermatologic Manifestations of Rheumatoid Arthritis. Rheumatology (Sunnyvale) 5: 168. doi: https://doi.org/10.4172/2161-1149.1000168.
Parodi A, Caproni M, Marzano AV, et al. Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol. 2002;82(1):48-51.
Guidolin, Fernanda, Esmanhotto, Letícia, Magro, Carlos Eduardo, Silva, Marilia Barreto, &Skare, Thelma L.. (2005). Prevalence of cutaneous findings in systemic sclerosis patients: experience of a teaching hospital. Anais Brasileiros de Dermatologia, 80(5), 481-486.
Tager RE, Rikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in black South Africans. Rheumatology. 1999; 38:397-400. PMID: 10371275. doi: https://doi.org/10.1093/rheumatology/38.5.397.
Patrícia Andrade de Macedo, Cláudia Teresa Lobato Borges, Romy Beatriz Christmann de Souza : Cyclophosphamide: effective in the treatment of severe cutaneous involvement in systemic sclerosis , Bras J Rheumatol 2009;49(3):265-75. DOI: http://dx.doi.org/10.1590/S0482-50042009000300008
OAI - Open Archives Initiative
